English | Español

Abbvie
Press release submission | Jul 24, 2021

DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients

Press release submission | Aug 15, 2020

ABBVIE: New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients
Press release submission | Nov 26, 2018

ABBVIE: Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
Press release submission | Sep 23, 2018

ABBVIE: Announces $5 Million Donation to Family Reach to Support Children Battling Cancer and Their Families
Carrie Bradon | Nov 28, 2017

AbbVie to take part in Evercore ISI Biopharma Catalyst conference
Kathy Adams | Nov 15, 2017

AbbVie executive to present at Jefferies London Healthcare Conference
Robert Hadley | Nov 7, 2017

FDA fast-tracking review for AbbVie’s endometriosis drug
Mark Iandolo | Nov 1, 2017

AbbVie to present abstracts on its investigational immunology medicine portfolio

Trending
+ Community
Patient Daily | Apr 17, 2025

ENT Practice Expert: OTO Forum 2025 will feature 'at least four topics that stand out as vital for doctors'
+ Pharmaceuticals
Patient Daily | Apr 17, 2025

UCSF neurosurgeon: 'The idea that 340B is about helping the poor is a fiction'
+ Pharmaceuticals
Patient Daily | Apr 22, 2025

National Consumers League CEO: 340B program abuse is 'a financial bonanza for non-profit hospitals'
+ Pharmaceuticals
Patient Daily | Apr 23, 2025

State Sen. Baldacci: 340B reform ‘could help hospitals alone to the tune of 50 to 70 million per year'